ACCP PHARMACOTHERAPY EXAM NEWEST 2025

EXAM ELABORATIONS Aug 28, 2025
Loading...

Loading document viewer...

Page 0 of 0

Document Text

  • | P a g e

pg. 1

ACCP PHARMACOTHERAPY EXAM NEWEST 2025

ACTUAL EXAM TEST BANK| COMPLETE 350 REAL

EXAM QUESTIONS AND CORRECT DETAILED

ANSWERS (VERIFIED ANSWERS WITH WELL

ELABORATED RATION ALES) GRADED A+|| NEW!!

(TO STUDY FOR THE BCPS EXAM)

A 76-year-old woman presents to the clinic with mild to moderate right knee pain related to osteoarthritis (OA). Her medical history is also significant for HTN, coronary artery disease, and hyperlipidemia. Her home drugs include carvedilol 25 mg twice daily, atorvastatin 20 mg daily, aspirin 81 mg daily. nitroglycerin 0.4 mg sublingually as needed for chest pain, and isosorbide dinitrate extended release 20 mg twice daily. Ranolazine 500 mg twice daily was just added to therapy regimen because of continued angina symptoms, patient's vital signs today include blood pressure 122/72 mm Hg and heart rate 66 beats/minute.She is allergic to penicillin and sulfonamides.Which of the following is the best recommendation for her OA-related pain?

  • Acetaminophen 500 mg every 4 hours,
  • Ibuprofen 800 mg every 4 hours.
  • Celecoxib 200 mg twice daily.

D. Tramadol 100 mg every 6 hours. - Correct Answer - A:

Acetaminophen 500 mg every 4 hours.

(According to the American College of Rheumatology osteoarthritis guidelines, acetaminophen should considered as first-line therapy for the management of mild to moderate knee or hip OA (Answer A is correct). 1 / 4

  • | P a g e

pg. 2 Although nonselective NSAIDs are also effective for OA, the dose of ibuprofen exceeds the maximal daily dose of 3200 mg and should be avoided because of the risk of cardiovascular events in a patient with controlled disease (Answer B is incorrect). Celecoxib can be used in dosages of up to 400 mg/day; however, it should be avoided in patients with poorly controlled coronary artery disease and in those allergic to sulfonamides (Answer C is incorrect).Tramadol is indicated for moderate to moderately severe pain and should used at doses Of no more than 300 mg/day in patients older than 75 years (Answer D is incorrect).)

A 76-year-old woman has bilateral knee OA pain that has not been sufficiently controlled with physical therapy, simple analgesics, systemic NSAIDs, or a short trial of opioid combination analgesics. Today, she presents to the clinic for follow-up. She is unable to perform many activities of daily living because she requires a walker, which considerably impairs her mobility.Which one of the following is the best long-term therapy option to address this patient's chronic pain?

  • Glucosamine 1500 mg and chondroitin 1200 mg/day.
  • Ketorolac 10 mg every 6 hours.
  • Morphine sulfate extended release 15 mg twice daily.
  • Intra-articular corticosteroid injection up to every 3 months as

needed. - Correct Answer - D: Intra-articular corticosteroid injection up

to every 3 months as needed.

(Intra-articular corticosteroids are the best choice to help alleviate this patient's chronic pain secondary to her OA of the knee. Although the 2 / 4

  • | P a g e

pg. 3 medication may take several days to reach maximal efficacy, it will offer her the most long-term pain relief with fewer systemic adverse reactions (Answer D is correct).According to the American College of Rheumatology guidelines for the treatment of OA, glucosamine and chondroitin are not recommended for patients with OA of the knee (Answer A is incorrect).Ketorolac will provide the most significant pain relief in the least amount of time, but use beyond 5 days increases the risk of

gastrointestinal bleeding: thus, ketorolac is not a long-term option for

this patient (Answer B is incorrect).Finally, the use of opioids for OA pain (and in the elderly) should discouraged of the increased of somnolence and unsteady gait (Answer C is incorrect).)

A 35-year-old woman has had rheumatoid arthritis (RA) for 10 years; her disease has been in remission for 6 months. She currently takes methotrexate 7.5 mg weekly and etanercept 50 mg weekly. The patient now states that she wants to become pregnant and asks about continuing her RA treatment during pregnancy.Which one of the following is the best recommendation for this patient?

  • Discontinue methotrexate and continue etanercept.
  • Discontinue methotrexate and etanercept and begin leflunomide.
  • Discontinue etanercept and continue low-dose methotrexate.

D. Discontinue all drugs. - Correct Answer - Answer A: Discontinue

methotrexate and continue etanercept.

  • / 4
  • | P a g e

pg. 4 (Patients with long-standing RA are likely to need maintenance therapy with disease-modifying antirheumatic drugs or biologics, even after achieving a short-term remission. Thus, discontinuing methotrexate, a known teratogen, to allow a possible pregnancy is reasonable while continuing etanercept, which largely appears safe in pregnancy (Answer A is correct; Answer C is incorrect).It would inappropriate to discontinue all drug treatment at once because the patient would likely suffer a flare of her RA symptoms (Answer D is incorrect).Substituting leflunomide would be inappropriate because it is also teratogenic (Answer B is incorrect).)

A 63-year-old man with HTN is referred to you for cardiovascular risk reduction, He takes lisinopril 20 mg daily and furosemide 20 mg daily.His BP is 135/78 mm Hg. Pertinent laboratory values include K 4.3 mEq/L and SCr 1.0 mg/dL. Fasting lipid profile is TC mg/dL, LDL-C 126 mg/dL, HDL-C 49 mg/dL, and TG 145 mg/dL. Using the Cohort Equation, his 10-year risk of atherosclerotic cardiovascular disease (ASCVD) is 14.3%.Which one of the following is to recommend for this patient?

  • Ezetimibe 10 mg daily.
  • Simvastatin 10 mg daily.
  • Pravastatin 20 mg daily.

D. Rosuvastatin 10 mg daily - Correct Answer - D: Rosuvastatin 10 mg

daily.

(According to the recent guideline recommendations, this meets the criteria for a statin-benefitting group (i.e., 40-75 years of age with LDL-

  • / 4

Download Document

Buy This Document

$30.00 One-time purchase
Buy Now
  • Full access to this document
  • Download anytime
  • No expiration

Document Information

Category: EXAM ELABORATIONS
Added: Aug 28, 2025
Description:

pg. 1 ACCP PHARMACOTHERAPY EXAM NEWEST 2025 ACTUAL EXAM TEST BANK| COMPLETE 350 REAL EXAM QUESTIONS AND CORRECT DETAILED ANSWERS (VERIFIED ANSWERS WITH WELL ELABORATED RATION ALES) GRADED A+|| NEW!...

Get this document $30.00